

1. DATE ISSUED MM/DD/YYYY 12/13/2018		1a. SUPERSEDES AWARD NOTICE dated except that any additions or restrictions previously imposed remain in effect unless specifically rescinded	
2. CFDA No. 93.977 - Preventive Health Services_Sexually Transmitted Diseases Control Grants			
3. ASSISTANCE TYPE Cooperative Agreement			
4. GRANT NO. 1 NH25PS005142-01-00 Formerly		5. TYPE OF AWARD Other	
4a. FAIN NH25PS005142		5a. ACTION TYPE New	
6. PROJECT PERIOD MM/DD/YYYY From 01/01/2019		Through MM/DD/YYYY 12/31/2023	
7. BUDGET PERIOD MM/DD/YYYY From 01/01/2019		Through MM/DD/YYYY 12/31/2019	

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Office of Financial Resources

1600 Clifton Road
Atlanta, GA 30329

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
[AWARD AUTHORITY NOT DEFINED FOR PS10-10136.NU2G]

8. TITLE OF PROJECT (OR PROGRAM)
Strengthening STD Prevention and Control for Health Departments (STD PCHD)

9a. GRANTEE NAME AND ADDRESS HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF Alternate Name: MISSOURI STATE DEPT/ HEALTH & SENIOR SRV 920 Wildwood Dr Jefferson City, MO 65109-5796	9b. GRANTEE PROJECT DIRECTOR Ms. Christine Smith 920 WILDWOOD DR JEFFERSON CITY, MO 65109-5796 Phone: 573-751-6439
--	--

10a. GRANTEE AUTHORIZING OFFICIAL Ms. Linda M. Cade 920 Wildwood Drive MISSOURI DEPARTMENT OF HEALTH & SENIOR SERVICES Jefferson City, MO 65109-5796 Phone: 573-751-6028	10b. FEDERAL PROJECT OFFICER Ms. Cassandra Davis 12 Corporate Blvd NE Brookhaven, GA 30329-1909 Phone: 404.498.3099
---	---

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)		12. AWARD COMPUTATION			
I Financial Assistance from the Federal Awarding Agency Only		a. Amount of Federal Financial Assistance (from item 11m) 1,662,974.00			
II Total project costs including grant funds and all other financial participation		b. Less Unobligated Balance From Prior Budget Periods 0.00			
a. Salaries and Wages 461,045.00	I	c. Less Cumulative Prior Award(s) This Budget Period 0.00			
b. Fringe Benefits 267,407.00		d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 1,662,974.00			
c. Total Personnel Costs 728,452.00		13. Total Federal Funds Awarded to Date for Project Period 1,662,974.00			
d. Equipment 0.00		14. RECOMMENDED FUTURE SUPPORT			
e. Supplies 40,204.00		(Subject to the availability of funds and satisfactory progress of the project):			
f. Travel 23,828.00		YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS
g. Construction 0.00		a. 2		d. 5	
h. Other 360,421.00		b. 3		e. 6	
i. Contractual 354,909.00		c. 4		f. 7	
j. TOTAL DIRECT COSTS 1,507,814.00		15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:		b	
k. INDIRECT COSTS 155,160.00	a. DEDUCTION				
l. TOTAL APPROVED BUDGET 1,662,974.00	b. ADDITIONAL COSTS				
m. Federal Share 1,662,974.00	c. MATCHING				
n. Non-Federal Share 0.00	d. OTHER RESEARCH (Add / Deduct Option)				
	e. OTHER (See REMARKS)				
16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:					
a. The grant program legislation.					
b. The grant program regulations.					
c. This award notice including terms and conditions, if any, noted below under REMARKS.					
d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.					
In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.					

REMARKS (Other Terms and Conditions Attached - Yes No)
New Award: Financial Assistance in the amount of \$1,662,974

GRANTS MANAGEMENT OFFICIAL:

Arthur Lusby, Grants Management Officer, Team Lead
2960 Brandywine Rd
Mailstop E15
Atlanta, GA 30341-5509
Phone: 770.488.2865

17. OBJ CLASS 41.51	18a. VENDOR CODE	18b. EIN	19. DUNS 878092600	20. CONG. DIST. 03	
FY-ACCOUNT NO.	DOCUMENT NO.	CFDA	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
21. a. 9-939ZRJQ	b. 19NH25PS005142	c. 93.977	d. PS	e. \$177,082.00	f. 75-19-0950
22. a. 9-939ZRPZ	b. 19NH25PS005142	c. 93.977	d. PS	e. \$1,485,892.00	f. 75-19-0950
23. a.	b.	c.	d.	e.	f.

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 12/13/2018
GRANT NO. 1 NH25PS005142-01-00	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 12/13/2018
GRANT NO. 1 NH25PS005142-01-00	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
01/01/2019	12/31/2019	Annual	03/30/2020
01/01/2020	12/31/2020	Annual	03/31/2021
01/01/2021	12/31/2021	Annual	03/31/2022
01/01/2022	12/31/2022	Annual	03/31/2023
01/01/2023	12/31/2023	Annual	03/30/2024

AWARD ATTACHMENTS

MISSOURI STATE DEPT/ HEALTH & SENIOR SRV

1 NH25PS005142-01-00

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **PS19-1901**, entitled “**Strengthening STD Prevention and Control for Health Departments (STD PCHD)**”, and application dated **July 30, 2018**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of **\$1,662,974.00** is approved for the Year **01** budget period, which is **January 1, 2019** through **December 31, 2019**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

This award has been fully funded for budget year 01.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds. CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO. CDC activities for this program are as follows:

Technical assistance and capacity building

- Work with recipients to identify capacity building assistance and technical assistance (TA) needs that are essential to the success of the project
- Provide access to training and TA, including via CDC-TRAIN, that will strengthen staff capacity relevant to all required strategies and activities of the program
- Assist recipients with enhancing health department workforce capacity and infrastructure by providing training and TA around skills assessment, core competencies and workforce development
- Provide STD clinical and laboratory consultation and STD reference diagnostic services
- Collaborate in assessing progress toward meeting strategic and operational goals/objectives and in establishing measurement and accountability systems for
 - documenting outcomes, such as increased performance improvements and best or promising practices

Information sharing

- Facilitate coordination, collaboration, and, where feasible, service integration among federal agencies, other CDC funded programs, other health departments, community based organizations, local and state planning groups, other CDC directly funded programs, medical care providers, laboratories, and others addressing STD prevention and control activities
- Collaborate to compile and disseminate accomplishments, best practices, performance criteria, and lessons learned during the period of performance
- Share information, best practices, lessons learned, and evaluation results among recipients through, for example: conferences, guidance, material development, webinars, data sharing publications, committees, conference calls, and working groups

Award guidance and monitoring

- Support recipients in implementing the requirements of the cooperative agreement, selecting or prioritizing prevention strategies/activities and meeting identified outcomes
- Monitor recipients' program performance using multiple approaches, such as routine calls, site visits, emails, conference calls, affinity group participation, and standardized review of performance, grantee feedback and other data reports
- Provide guidance and coordination to recipients to improve the quality and effectiveness of work plans, evaluation strategies, products and services, and collaborative activities with other organizations
- Provide requirements and expectations for standardized and other data reporting, monitoring, and evaluation

Budget Revision Requirement: By **February 4, 2019** the recipient must submit a revised budget with a narrative justification. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

- Recipients may not use funds for research.
- Recipients may not use funds for clinical care except as allowed by law.
- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.

- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of
 - legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
- See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients.
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- In accordance with the United States Protecting Life in Global Health Assistance policy, all non-governmental organization (NGO) applicants acknowledge that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. See Additional Requirement (AR) 35 for applicability (<https://www.cdc.gov/grants/additionalrequirements/ar-35.html>).

Funding restrictions specific to this NOFO

- Recipients may not use funds to purchase HIV Pre-exposure Prophylaxis (PrEP) medications or family planning medications.
- Recipients may not use funds to purchase STD medications, other than noted in this NOFO, unless they receive prior approval from CDC.
- STD-related HIV prevention activities should be conducted under this cooperative agreement, but they should not exceed ten percent (10%) of program effort and allocation.
- Applicants may provide assistance, no more than 10% of the overall amount, without prior approval from CDC, to not-for-profit or government clinics that can document their ability to provide safety-net STD clinical preventive services as per CDC guidance.

Indirect Costs: Indirect costs are approved based on the negotiated indirect cost rate agreement dated **March 9, 2018**, which calculates indirect costs as follows, a **Provisional** is approved at a rate of **21.3%** of the base, which includes, **direct salaries and wages including all fring benefits**. The effective dates of this indirect cost rate are from **July 1, 2018** to **June 30, 2021**.

REPORTING REQUIREMENTS

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, “Performance Progress and Monitoring Report”, Expiration Date 8/31/2019.** The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html>.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Portia R. Brewer, Grants Management Specialist
Centers for Disease Control and Prevention
Infectious Diseases Services Branch
2920 Brandywine Road, MS E-15
Atlanta, GA 30341
Fax: N/A
Email: pbrewer@cdc.gov (Include “Mandatory Grant Disclosures” in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include “Mandatory Grant Disclosures” in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for

failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PROGRAM OR FUNDING GENERAL REQUIREMENTS

HIV Program Review Panel Requirement: All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application. All award funds must be tracked and reported separately.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Document Number: **19NH25PS005142**

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:

Portia R. Brewer, M.B.A.
Grants Management Specialist
Centers for Disease Control and Prevention
Infectious Diseases Services Branch
2920 Brandywine Road, MS E-15
Atlanta, GA 30341
Telephone: (770) 488-3185
Email: pbrewer@cdc.gov

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Programmatic Contact:

Cassandra Davis, Project Officer
Centers for Disease Control and Prevention
National Center for HIV, Viral Hepatitis, STD & TB Prevention
12 Corporate Square
Atlanta GA 30329
Telephone: (404) 498-3099
Fax: N/A
Email: vts4@cdc.gov

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

GMO Contact:

Arthur C. Lusby, M.B.A.
Grants Management Officer
Centers for Disease Control and Prevention
Infectious Diseases Services Branch
2920 Brandywine Road, MS E-15
Atlanta, GA 30341
Telephone: (770) 488-2685
Email: ALusby@cdc.gov